Delving into the Latest Updates on Ampicillin Sodium/Sulbactam Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ampicillin Sodium and Sulbactam Sodium, Ampicillin/Sulbactam, Sulbactam sodium/Ampicillin Sodium

+ [25]

Target

PBPs x β-lactamase

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [4]

Active Indication

CystitisLung AbscessPeritonitis+ [11]

Inactive Indication

Community Acquired PneumoniaPneumonia, Bacterial

Originator Organization

Active Organization

+ [5]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 1986),

Bone and joint infectionsCentral Nervous System InfectionsGynecological infection+ [6]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H30N4Na2O9S2

InChIKeyMWBFWOYZSJLWIO-UBWQYZJSSA-N

CAS Registry117060-71-6

CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall.
Current treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides (Amikacin, Gentamicin), which are limited by resistance, and tetracyclines (Tigecycline, Eravacycline), which are effective against CRAB. Fosfomycin is effective in combination treatments, and combination therapy (e.g., colistin with sulbactam, fosfomycin, or eravacycline) can enhance outcomes.
Previous research shows promise for combination therapies, improving treatment efficacy and reducing mortality. New regimens are being studied to find optimal combinations. Individualized dosing is crucial, considering patient-specific factors like age, weight, and renal function. Adjustments depend on the infection site and comorbidities.
Strict infection control and antimicrobial stewardship programs (ASPs) are essential. ASPs focus on optimizing antibiotic use and reducing resistance through education and surveillance. Future directions include continued research for new drugs or combinations and strategies to overcome resistance and improve treatment efficacy.
Study goals include achieving negative samples after 10 days of therapy, 30-day survival, discharge rates, reduced SOFA scores, and improved clinical and radiological findings. A randomized study will compare colistin combined with fosfomycin, ampicillin/sulbactam, and eravacycline.
In summary, treating CRAB infections is complex, requiring combination therapy, individualized dosing, and strict infection control measures.

Start Date30 Jan 2025

Sponsor / Collaborator-

NCT06735703

/ Not yet recruitingNot ApplicableIIT

Incidince of PROM with GBS Infection and Prophylaxis Against It

To investigate incidince of prom with GBS infection and role of prophylaxis against it

Start Date25 Dec 2024

Sponsor / Collaborator

Assiut University

NCT06494072

/ RecruitingPhase 4IIT

Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.

The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia.
The main questions it aims to answer are:
* Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children?
* Does a 5 day course cause less antibiotic side effects compared to a standard (longer) course of antibiotics in children with community acquired pneumonia?
Participants will
* be randomly assigned to either receive 5 total days or a total duration decided by the treating physician
* receive a brief follow up questionnaire regarding clinical symptoms, follow up care/antibiotics, and side effects via phone or email at days 5 and 14 from the start of antibiotics
Researchers will compare the experimental group (receiving 5 days duration) with the control group (standard duration) to see if 5 days is as successful as a standard duration.

Start Date22 Aug 2024

Sponsor / Collaborator

Medical College of Wisconsin

100 Clinical Results associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

100 Translational Medicine associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

100 Patents (Medical) associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

475

Literatures (Medical) associated with Ampicillin Sodium/Sulbactam Sodium

06 Feb 2025·Journal of the Pediatric Infectious Diseases Society

Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children

Article

Author: Tamma, Pranita D ; Lockowitz, Christine R ; Stimes, Grant ; Bio, Laura L ; Girotto, Jennifer E ; Morrisette, Taylor ; Dassner, Aimee M ; Gainey, Andrew B ; Hsu, Alice J ; Iacono, Denise ; Wilson, William S ; Tran, M Tuan ; Chiotos, Kathleen

AbstractThe Infectious Diseases Society of America (IDSA) publishes annual guidance on the treatment of antimicrobial-resistant (AMR) gram-negative infections. Within the AMR guidance, suggested dosages of antibiotics for adults infected with AMR pathogens are provided. This document serves as a companion document to the IDSA guidance to assist pediatric specialists with dosing β-lactam agents for the treatment of AMR infections in children. A panel of 13 pediatric infectious diseases specialists, including 11 pharmacists and 2 physicians, reviewed existing pharmacokinetic/pharmacodynamic, animal, and clinical data for newer β-lactam agents that are available in the United States and suggested for the treatment of AMR infections (ie, cefiderocol, ceftazidime-avibactam, ceftazidime-avibactam and aztreonam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam). Suggested dosing for ampicillin-sulbactam is also provided, given complexities in dosing for carbapenem-resistant Acinetobacter baumannii infections. Consensus-based suggested dosing for β-lactam agents used to treat AMR infections in neonates, infants, children, and adolescents and relevant supporting evidence are provided. Content is up to date as of December 1, 2024. Gaps and limitations to existing data are discussed. Optimizing antibiotic dosing is critical to improving the outcomes of children with AMR infections.

01 Jan 2025·International Wound Journal

RETRACTION: Effect of Clindamycin Compared with Ampicillin‐Sulbactam as Prophylactic Antibiotics for Wound Infections Following Major Surgery for Head and Neck Cancer: A Meta‐Analysis

RETRACTION:

Y.

Hu,

A.

Yan, and

F.

Jiang, “,” International Wound Journal20, no. (2023): 4151–4158, https://doi-org.libproxy1.nus.edu.sg/10.1111/iwj.14312.

The above article, published online on 22 July 2023, in Wiley Online Library (http://onlinelibrary.wiley.com.libproxy1.nus.edu.sg/), has been retracted by agreement between the journal Editor in Chief, Professor Keith Harding; and John Wiley & Sons Ltd. Following an investigation by the publisher, all parties have concluded that this article was accepted solely on the basis of a compromised peer review process. The editors have therefore decided to retract the article. The authors disagree with the retraction.

01 Jan 2025·China CDC Weekly

Characterization of <i>Aeromonas</i> Strains Isolated from Adult Patients with Diarrhea and Aquatic Environments — Beijing Municipality, China, 2016–2022

Article

Author: Wang, Luotong ; Yu, Keyi ; Liu, Shengtian ; Wang, Duochun ; Li, Jun ; Wang, Yuanyuan ; Peng, Tao ; Li, Ying ; Huang, Zhenzhou ; Wang, Miao ; Liu, Yuwei ; Kang, Ying ; Li, Shoufei ; Yan, Aixia ; Du, Xiaoli

IntroductionAeromonas is widely distributed in aquatic environments. This study describes the pathogenic characteristics of Aeromonas isolated from adult diarrhea patients and aquatic environments in Beijing, China.MethodsAeromonas isolates from patients with diarrhea and river water samples were assessed using whole-genome sequencing (WGS) and antibiotic resistance profiling.ResultsIn total, 38 Aeromonas isolates were collected. Among these, 13 isolates were from patients with common clinical symptoms, including diarrhea, abdominal pain, and nausea. Four of 13 Aeromonas-positive patients were co-infected with other intestinal pathogens. Patient-derived Aeromonas isolates showed high resistance to ampicillin, ampicillin-sulbactam, nalidixic acid, and tetracycline, whereas water-derived isolates showed high resistance to ampicillin, ampicillin-sulbactam, and nalidixic acid. Phylogenetic analysis revealed seven independent branches, without significant clustering among patient- and water-derived isolates.ConclusionsThis study provides valuable insights into the prevalence and characteristics of Aeromonas. The intertwined distribution of patient- and water-derived isolates in the phylogenetic tree deserves attention.

100 Deals associated with Ampicillin Sodium/Sulbactam Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01CR01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cystitis	Japan	Pfizer Japan, Inc.	01 Jul 1994
Lung Abscess	Japan	Pfizer Japan, Inc.	01 Jul 1994
Peritonitis	Japan	Pfizer Japan, Inc.	01 Jul 1994
Pneumonia	Japan	Pfizer Japan, Inc.	01 Jul 1994
Bacterial Infections	China	Zhongshan Lienpu Pharmaceutical Co., Ltd	01 Jan 1993
Bone and joint infections	United States	Pfizer Inc.	31 Dec 1986
Central Nervous System Infections	United States	Pfizer Inc.	31 Dec 1986
Gynecological infection	United States	Pfizer Inc.	31 Dec 1986
Intraabdominal Infections	United States	Pfizer Inc.	31 Dec 1986
Lower Respiratory Tract Infections	United States	Pfizer Inc.	31 Dec 1986
Respiratory Tract Infections	United States	Pfizer Inc.	31 Dec 1986
Sepsis	United States	Pfizer Inc.	31 Dec 1986
Skin and skin structure infections	United States	Pfizer Inc.	31 Dec 1986
Urinary Tract Infections	United States	Pfizer Inc.	31 Dec 1986

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Community Acquired Pneumonia	Preclinical	Japan	Pfizer Inc.	01 Oct 2010
Pneumonia, Bacterial	Preclinical	Japan	Pfizer Inc.	01 Oct 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00760006 (CTgov)	Phase 2	Cleft Palate	224	Unasyn (Unasyn Antibiotic Arm)	ichrzxtvyy(kzgzcbddti) = begpzrnjwa wzcdjwkoag (sdfnqthovh, dbzmptflfg - bjozpvspqf) View more	-	01 Feb 2018
				saline solution (Saline Placebo Arm)	ichrzxtvyy(kzgzcbddti) = kqumkdoict wzcdjwkoag (sdfnqthovh, lgqkpdurxw - xzvdmimqis) View more
NCT00879190 (CTgov)	Phase 2/3	Chorioamnionitis	92	Unasyn (Unasyn (Ampicillin/Sulbactam))	vnasmjyvob(rvwegqisrl) = ueadasredd iaqoetvler (wwzigdffdw, fgdbbckelx - uewqblpjen) View more	-	15 Mar 2017
				gentamicin+Ampicillin (Ampicillin/Gentamicin)	vnasmjyvob(rvwegqisrl) = ugprvdvney iaqoetvler (wwzigdffdw, btvgesnpop - euxftykodj) View more
ERS2015	Not Applicable	Community Acquired Pneumonia	-	Ampicillin-sulbactam + Macrolide	(eatozbvbdx) = xfjlebouct dytbhxfrmv (vijctnycfz ) View more	Positive	01 Sep 2015
				Fluoroquinolone	(eatozbvbdx) = hfgjsycvor dytbhxfrmv (vijctnycfz ) View more
NCT00356148 (Pubmed \| Ann Surg)	Phase 4	Breast Cancer	369	prophylactic antibiotic administration (Prophylaxis group)	spneyfwveo(cqutnpwawh) = nehdzxrjpy jcccohkelr (ygxzoeyvny ) View more	Positive	01 Jan 2013
				prophylactic antibiotic administration (Control group)	spneyfwveo(cqutnpwawh) = trxiskbixd jcccohkelr (ygxzoeyvny ) View more
NCT00368537 (CTgov)	Phase 4	Skin Diseases, Bacterial \| Skin and skin structure infections \| Soft Tissue Infections	550	Tigecycline (Tigecycline)	lzskcuhypw(vwjzyscpun) = dovqvsjtoj ipxavhqenj (ryuvbjnxlb, hdulzcirqc - jdtzahjubo) View more	-	09 Aug 2012
				Ampicillin-Sulbactam+Amoxicillin-Clavulanate (Ampicillin-Sulbactam or Amoxicillin-Clavulanate)	lzskcuhypw(vwjzyscpun) = vdqdteomhu ipxavhqenj (ryuvbjnxlb, jhpiqjuzqh - dekntzkgbp) View more
NCT01189487 (CTgov)	Phase 3	Pneumonia, Bacterial \| Community Acquired Pneumonia	47	ampicillin sodium/sulbactam sodium	hevpmvbkym(masgejassg) = idnmsflzad nlvlyboycr (pggobjqfgp, htguvjhztn - okxgaxpslu) View more	-	18 May 2012
ASN2011	Not Applicable	Acute Kidney Injury	12	Ampicillin/Sulbactam 2g/1g	spkrwfeoln(yrzgdqoriq) = elfselewup yzabdxbzmy (dpqhsjxybe, 7.7)	Positive	08 Nov 2011
NCT01138852 (Pubmed \| BMC Infect Dis)	Phase 4	-	176	Ampicillin-sulbactam	sgpiffoosk(wzenrpjpwg) = exmcnmoavp lngdittklh (elhbrxxsfp )	-	30 Nov 2010
				Cefuroxime	sgpiffoosk(wzenrpjpwg) = insqwbglzx lngdittklh (elhbrxxsfp )